Bu içeriği görüntülemek için JoVE aboneliği gereklidir. Oturum açın veya ücretsiz deneme sürümünü başlatın.
Method Article
Flow cytometry is a powerful tool allowing for the isolation and study of specific cell populations. This protocol describes steps for isolating LacZ-expressing cells from cochlear tissues from neonatal transgenic mice. Dissociated cochlear cells were labeled using fluorescent-conjugated substrates of β-galactosidase prior to separation via flow cytometry.
Isolation of specific cell types allows one to analyze rare cell populations such as stem/progenitor cells. Such an approach to studying inner ear tissues presents a unique challenge because of the paucity of cells of interest and few transgenic reporter mouse models. Here, we describe a protocol using fluorescence-conjugated probes to selectively label LacZ-positive cells from the neonatal cochleae.
The most common underlying pathology of sensorineural hearing loss is the irreversible damage and loss of cochlear sensory hair cells, which are required to transduce sound waves to neural impulses. Recent evidence suggests that the murine auditory and vestibular organs harbor stem/progenitor cells that may have regenerative potential1,2. These findings warrant further investigation, including identifying specific cell types with stem/progenitor cell characteristics. The Wnt signaling pathway has been demonstrated to play a critical role in maintaining stem/progenitor cell populations in several organ systems3-7. We have recently identified Wnt-responsive Axin2-expressing cells in the neonatal cochlea, but their function is largely unknown8.
To better understand the behavior of these Wnt-responsive cells in vitro, we have developed a method of isolating Axin2-expressing cells from cochleae of Axin2-LacZ reporter mice9. Using flow cytometry to isolate Axin2-LacZ positive cells from the neonatal cochleae, we could in turn execute a variety of experiments on live cells to interrogate their behavior as stem/progenitor cells. Here, we describe in detail the steps for the microdissection of neonatal cochlea, dissociation of these tissues, labeling of the LacZ-positive cells using a fluorogenic substrate, and cell sorting. Techniques for dissociating cochleae into single cells and isolating cochlear cells via flow cytometry have been described2,10-12. We have made modifications to these techniques to establish a novel protocol to isolate LacZ-expressing cells from the neonatal cochlea.
1. Microdissection of the cochlea
2. Cell dissociation (modified from previously described methods)2,10
3. Flow Cytometry
4. Representative Results (see Figure 2):
With the above protocol, we typically recover 40-45% debris-free cells from both the wildtype and Axin2LacZ/+ cochleae (Figures 2A and B), with about 70% of them free of doublets (see Figures 2A' and B'). Most sorted cells are viable and did not take up PI (~95%) (Figures 2A'' and B''). On average, the top ~20% CUG-positive cells are considered Axin2-LacZ-positive cells (Figure 2B''') and correlate to about 15,000 Axin2-LacZ-high cells per 10-12 animals.
Flow cytometry re-sort analysis of Axin2-high cells revealed greater than 93% purity in the Cascade Blue channel. In order to further confirm the identity of these cells, we performed post-sort immunostaining of both Axin2-high and Axin2-low cells using anti-β-galactosidase antibodies, and found that the Axin2-high cells contained ~93.4% β- galactosidase-positive cells (greater than 1,500 cells analyzed) and that Axin2-low cells contained ~4.8% β-galactosidase-positive cells.
Figures and Tables:
Figure 1.Experimental paradigm. The above figure depicts the overall experimental strategy and techniques as described through the protocol section. Cochleae from wildtype and Axin2LacZ/+ mice are harvested and dissociated into single cells, which were then treated with CUG, a fluorescent substrate for β-galactosidase. Axin2-LacZ-high and -low cells were then separated out via flow cytometry. Click here to view a full-sized version of this image.
Figure 2.Gating Strategies. This figure illustrates the flow cytometry gating strategies used. A) Dissociated wildtype cells that underwent the same treatment as Axin2-LacZ cells are analyzed here using a total of 10,000 events. The first panel demonstrates the side scatter area (SSC-A) versus forward scatter area (FSC-A). Here, a distinct group of events are of a much larger size than those events closer to the y-axis. These events are designated as the "Debris Negative." The next gate, A', analyzes the "Debris Negative" cells from panel A, which is 43.8% of the total number of events (see table below). In this panel, the forward scatter height (FSC-H) versus the FSC-A is used to exclude doublets. Events deviating from the expected linear nature of the plot are excluded. This preparation typically yields ~70% events within the designated gate, and the remaining cells are excluded. In panel A'', propidium iodide (PI) as detected by the PE-Cy5 channel, is used to label dead cells (5.3%). In the next panel (A'''), the Cascade blue channel is used to detect the fluorescent substrate CUG. Here, the LacZ-high gates include less than 1% of total events. B) Dissociated cells from Axin2-LacZ mice treated with CUG and PI are analyzed here using a total of 10,000 events. Identical gates from panel A are applied here. B' shows that 29.5% of cells are excluded as doublets while B'' demonstrates that 5.4% are not viable. The initial gates for LacZ-high and -low cells are drawn using panel B''' with LacZ-high initially set at 19.7% and LacZ-low at 20.4%. Click here to view a full-sized version of this image.
Event number | Percentage | ||
A | Wildtype Analysis | 10,000 | |
A' | Debris Negative | 4,381 | 43.80% |
A'' | Doublet Negative | 3,116 | 71.10% |
A''' | PI Negative | 2,951 | 94.70% |
LacZ-high | 16 | 0.54% | |
LacZ-low | 2,790 | 94.50% | |
B | Axin2-LacZ Analysis | 10,000 | |
B' | Debris Negative | 4,218 | 42.2% |
B'' | Doublet Negative | 2,973 | 70.50% |
B''' | PI Negative | 2,813 | 94.6% |
LacZ-high | 553 | 19.70% | |
LacZ-low | 573 | 20.40% |
Table 1. Quantitative analyses of gating strategies in Figure 2.
Access restricted. Please log in or start a trial to view this content.
Independent research studies have characterized limited regenerative capacity within the neonatal cochleae2,10,12,13. Using a GFP-reporter mice and flow cytometry, White and colleagues isolated specific cochlear supporting cells and found them to have progenitor cell characteristics12.
The canonical Wnt pathway has been demonstrated to mark stem/progenitor cell populations in multiple organ systems including the brain, mammary gland, hematopoietic system, skin, and gastro...
Access restricted. Please log in or start a trial to view this content.
No conflicts of interest declared.
We thank S. Heller, K. Oshima, R. Nusse, and Y. Zeng for fruitful discussions and C. Tang, A. Lee, E. Liaw, and the Stanford Shared FACS Facility staff for technical assistance. This work was supported by Howard Hughes Medical Institute Medical Research Training Fellowship, Stanford University Medical Scholars program (both to T.A.J.), Stanford University Dean's Fellowship (to R.C.), American Otological Society, Triological Society, Percy Memorial Award, the Akiko Yamazaki and Jerry Yang Faculty Scholar Fund, and NIDCD/NIH K08 DC011043 (all to A.G.C.).
Access restricted. Please log in or start a trial to view this content.
Name | Company | Catalog Number | Comments |
Petri dish, polystyrene, sterile Geriner Bio-one 35 x 10 mm | VWR international | 82050-540 | |
BD Falcon Cell Strainers, Sterile, BD Biosciences, blue, 40 μm | VWR international | 21008-949 | |
Hanks’ Balanced Salt Solution (HBSS). Solution with Calcium, Magnesium, and without Phenol Red, Sterile | VWR international | 45000-456 | |
Cellstar centrifuge tubes, polypropylene, sterile, greiner bio-one, 50 ml | VWR international | 82050-346 | |
Cellstar centrifuge tubes, polypropylene, sterile, greiner bio-one, 15 ml | VWR international | 82050-278 | |
B-27 Serum-Free Supplement (50x), liquid | Invitrogen | 17504-044 | |
N-2 Supplement (100x), liquid | Invitrogen | 17502-048 | |
bFGF, fibroblast growth factor-basic human | Sigma-Aldrich | F0291 | |
IGF-1, insulin-like growth factor-1 from mouse | Sigma-Aldrich | I8779 | |
EGF, epidermal growth factor human | Sigma-Aldrich | E9644 | |
Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 50/50 Mix: 1X, with L-Glutamine and 15 mM HEPES | VWR international | 45000-350 | |
BD Falcon Round-Bottom Tubes, Disposable, Polystyrene, 12x75 | VWR international | 60819-295 | |
Trypsin, 0.25% (1X) with EDTA 4Na, liquid | Invitrogen | 25200-056 | |
ep Dualfilter TIPS 300uL, 960 TIPS | Eppendorf | 22491245 | |
Trypsin Inhibitor, Soybean, Purified | Worthington Biochemical | LS003570 | |
BD Falcon 40um Cell Strainers | BD Biosciences | 21008-949 | |
Multiwell Plates, Polystyrene, Greiner Bio-One, Nontreated Plates, 6 wells | VWR international | 82050-846 | |
Marker Gene FACS Blue LacZ beta-Galactosidase Detection Kit | Marker Gene Technologies | M0255 |
Access restricted. Please log in or start a trial to view this content.
Bu JoVE makalesinin metnini veya resimlerini yeniden kullanma izni talebi
Izin talebiThis article has been published
Video Coming Soon
JoVE Hakkında
Telif Hakkı © 2020 MyJove Corporation. Tüm hakları saklıdır